| Autor: |
Lima, Ana Lucia L., Oliveira, Priscila R., Paula, Adriana P., Dal-Paz, Karine, Rossi, Flavia, Zumiotti, Arnaldo V. |
| Zdroj: |
Infection Control & Hospital Epidemiology; May 2009, Vol. 30 Issue: 5 p487-490, 4p |
| Abstrakt: |
We sought to evaluate the indirect impact of ertapenem use for the treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae infections in our hospital on the susceptibility of Pseudomonas aeruginosato imipenem. The use of ertapenem was mandated for treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae infections in the absence of nonfermenting gram-negative bacilli for 1 year. The use of imipenem was restricted. Imipenem consumption decreased 64.5%. Ertapenem consumption was 42.57 defined daily doses per 1,000 patient-days. None of the 18 P. aeruginosaisolates recovered after ertapenem introduction were imipenem-resistant, compared with 4 of the 20 P. aeruginosaisolates recovered in the previous year. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
